← boardnext 2026-09
GPCR
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeuticsdistress 4/10 · elevated risk$52.32+4%today-44% from 52w high
Lead: obesity · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$1459M
Runway
9.4 yrs
Shares 1y
+23%
Price & events
-43.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
+3.8%
1D
+13.7%
1W
+14.7%
1M
+11.3%
3M
-42.1%
6M
+188.1%
1Y
+45.6%
2Y
—
5Y
+101.2%
All
Overview
- Market Cap
- $11.16B
- Volume
- 66.61K
- 52 Week Range
- $16.20 – $93.79
- Total Shares
- 213.22M
- Float Shares
- 54.91M
- Short %
- 11.82%
- % Held by Insiders
- 2.66%
- % Held by Institutions
- 96.05%
- RVOL
- 0.09x
- Beta
- -1.57
Pipeline stages · 1 programs
Aleniglipron
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 4 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 final ~2027-08-31 | Phase 2 | — | Obesity, Overweight, or Chronic Weight Management | — | active not recruiting |
| 2026-09 Estimated 50% readout ~2026-10-16 | Phase 2 | Aleniglipron | Obese, Obesity, Obesity Type 2 Diabetes Mellitus, Weight Loss | — | active not recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | Aleniglipron | Obesity, Overweight, Chronic Weight Management | — | not yet recruiting |
| 2028-09 Estimated 50% readout ~2028-11-15 | Phase 3 | aleniglipron | Obesity, Overweight, Chronic Weight Management, Type2 Diabetes Mellitus | — | not yet recruiting |
Upcoming readouts & decisions · our signals
2 upcoming events have our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 13
- Q4 2026Guided 70%readoutPhase 2aleniglipron · Data from Type 2 Diabetes / Obesity studySEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 3aleniglipron · Initiate Phase 3 programSEC 8-K
- Q4 2026Guided 70%trial initiationsecondaryPhase 1ACCG-3535 · Initiation of Phase 1 clinical studySEC 8-K
- Q3 2026Guided 70%trial initiationsecondaryPhase 1ACCG-2671 · Initiation of multiple ascending dose (MAD) studySEC 8-K
- Q3 2026Guided 70%trial initiationsecondaryPhase 3aleniglipron · Initiation of Phase 3 program for chronic weight managementSEC 8-K
- Q3 2026Guided 70%readoutPhase 2aleniglipron · Topline data from ACCESS open label extension studySEC 8-K
- Q3 2026Guided 70%readoutPhase 1ACCG-2671 · Initial data from Phase 1 SAD studySEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026trial initiationsecondaryPhase 3aleniglipron · Initiate Phase 3 clinical programSEC 8-K
- first half of 2026readoutPhase 2aleniglipron · Topline results from ACCESS program studies (Phase 2b ACCESS, ACCESS II, body composition, OLE)SEC 8-K
- 2026-05-07fda agreementaleniglipron · Positive end-of-Phase 2 feedback received from FDASEC 8-K
- by year end 2025trial initiationsecondaryPhase 1ACCG-2671 · Initiation of Phase 1 clinical study for ACCG-2671SEC 8-K
- fourth quarter of 2024trial initiationsecondaryPhase 2GSBR-1290 · Phase 2b clinical development initiationSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $105 (+100% upside) · 16 analysts
- 2026-06-11HC Wainwright & Co.Buy
- 2026-04-27Canaccord GenuityBuy
- 2026-03-16HC Wainwright & Co.Buy
- 2026-03-02HC Wainwright & Co.Buy
- 2026-02-27CitizensMarket Outperform
- 2026-01-22JP MorganOverweight
Competitors — obesity
- LLYELI LILLY & Co$1094.4B · D3
- AMGNAMGEN INC$195.4B · D3
- RYTMRHYTHM PHARMACEUTICALS, INC.$7.0B · D0
- MBXMBX Biosciences, Inc.$2.8B · D2
- WVEWave Life Sciences Ltd.$1.1B · D1
- CRBPCorbus Pharmaceuticals Holdings, Inc.$164M · D7
- GUTSFRACTYL HEALTH, INC.$123M · D9
- VANIVivani Medical, Inc.$118M · D7
- MTVAMetaVia Inc.$8M · D7
- NONOFNOVO NORDISK A S— · D2
Recent news
- 2026-07-21Restore Vision and Forge Biologics Announce AAV Development and cGMP Manufacturing Partnership - Business Wire
- 2026-07-21Structure Therapeutics Inc. (GPCR) Stock Analysis: A Biotech Contender with 122.63% Potential Upside - DirectorsTalk Interviews
- 2026-07-19(GPCR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
- 2026-07-16Form 4 Structure Therapeutics Inc ADR For: 15 July - Investing.com India
- 2026-07-16Form 4 Structure Therapeutics Inc ADR For: 15 July By Investing.com - Investing.com Nigeria
- 2026-07-15Structure Therapeutics (NASDAQ: GPCR) CSO exercises options and sells ADS - Stock Titan
- 2026-07-14Metaphore Biotechnologies Announces Formation of Scientific Advisory Board to Advance the Next Era of Antibody Medicines - Business Wire
- 2026-07-08Structure Therapeutics (GPCR) Morgan Stanley 23rd Annual Global Healthcare Conference summary - Quartr
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.